CLIA Kit for Tumor Protein p53 (P53) Homo sapiens (Human) Sandwich CLIA

TP53; LFS1; TRP53; Li-Fraumeni Syndrome; Cellular tumor antigen p53; Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Tumor Protein p53 (P53) Packages (Simulation)
  • CLIA Kit for Tumor Protein p53 (P53) Packages (Simulation)
  • CLIA Kit for Tumor Protein p53 (P53) Results demonstration
  • SCA928Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Tumor Protein p53 (P53) and the recovery rates were calculated by comparing the measured value to the expected amount of Tumor Protein p53 (P53) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 90-104 93
EDTA plasma(n=5) 96-105 101
heparin plasma(n=5) 90-102 94

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tumor Protein p53 (P53) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tumor Protein p53 (P53) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tumor Protein p53 (P53) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-92% 83-102% 85-99% 80-98%
EDTA plasma(n=5) 96-104% 86-101% 86-102% 78-93%
heparin plasma(n=5) 90-97% 91-98% 88-99% 93-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Tumor Protein p53 (P53)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Tumor Protein p53 (P53). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Tumor Protein p53 (P53). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Tumor Protein p53 (P53) level in the sample or standard.;

Citations

  • Analysis of p53 and miRNA expression after irradiation of glioblastoma cell linesPubMed: 23155233
  • Therapeutic role of curcumin in oxidative DNA damage caused by formaldehydePubMed: 25761397
  • Supplementation with Selenium yeast on the prooxidant–antioxidant activities and anti-tumor effects in breast tumor xenograft-bearing micePubMed: 26344777
  • Transcription factor HBP1: A regulator of senescence and apoptosis of preadipocytesPubmed: 31331641
  • Effect of Graviola (Annona Muricata l.) and Ginger (Zingiber Officinale Roscoe) on Diabetes Mellitus Induced in Male Wistar Albino Rats
  • Non-POU Domain-Containing Octamer-Binding (NONO) Protein Stability Regulated by PIN1 is Crucial for Breast Cancer Tumorigenicity Via the MAPK/β …

Recommend products